The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155).
 
David S. Miller
Consulting or Advisory Role - Alexion Pharmaceuticals; AstraZeneca; Clovis Oncology; Eisai; Genentech; Guardant Health; ImmunoGen; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech
Research Funding - Aeterna Zentaris (Inst); Aprea AB (Inst); AstraZeneca (Inst); Genentech (Inst); ImmunoGen (Inst); Janssen Biotech (Inst); Pfizer (Inst); Takeda (Inst); Tesaro (Inst); TRACON Pharma (Inst); Xenetic Biosciences (Inst)
 
Giovanni Scambia
No Relationships to Disclose
 
Igor Bondarenko
No Relationships to Disclose
 
Anneke M. Westermann
No Relationships to Disclose
 
Ana Oaknin
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Tesaro
Travel, Accommodations, Expenses - AstraZeneca; PharmaMar; Roche
 
Amit M. Oza
Honoraria - Intas
Research Funding - AstraZeneca (Inst); Immunovaccine (Inst)
Travel, Accommodations, Expenses - AstraZeneca
 
Alla Sergeevua Lisyanskaya
No Relationships to Disclose
 
Ignace Vergote
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Karyopharm Therapeutics (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Tesaro (Inst); Vifor Pharma (Inst); Wyeth (Inst)
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche
 
Robert Michael Wenham
Stock and Other Ownership Interests - Ovation Sciences
Honoraria - Clovis Oncology; Tesaro
Consulting or Advisory Role - Clovis Oncology; Genentech; Ovation Sciences; Tesaro
Speakers' Bureau - Clovis Oncology; Genentech; Tesaro
Research Funding - Merck (Inst); Prescient Therapeutics (Inst); TapImmune Inc. (Inst)
 
Sarah Madhu Temkin
Honoraria - AstraZeneca
Research Funding - Aprea AB (Inst); Macrogenics (Inst)
Expert Testimony - Johnson & Johnson
 
Hani Gabra
No Relationships to Disclose